AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

Zacks Investment Research • Aug 12, 2026

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

Zacks Investment Research • Aug 12, 2026

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

Zacks Investment Research • Aug 12, 2026

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Investment Research • Aug 11, 2026

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization  Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.

GlobeNewsWire • Aug 10, 2026

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 7, 2026

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

Zacks Investment Research • Jul 31, 2026

Amneal Pharmaceuticals Q2 Earnings Call Highlights

Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.

MarketBeat • Jul 30, 2026

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Amneal Reports Second Quarter 2026 Financial Results

–  Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost –

GlobeNewsWire • Jul 30, 2026